Novartis

News

Novartis bid to block generic Entresto in US suffers setback

An appeals court in the US has declined to overturn an attempt by Novartis to block the launch of a generic of its heart failure blockbuster Entresto.

News

Woman pushing man in wheelchair along beachfront as sun sets

Novartis pays $1bn upfront for Huntington's drug from PTC

Novartis has made a return to the Huntington's disease stage by licensing an oral mRNA splicer from PTC Therapeutics for $1 billion upfront.

News

Kisqali gets early breast cancer approval in Europe

Novartis' fast-growing breast cancer drug gets another growth driver as EU approves adjuvant use in patients with early-stage HR+, HER2- tumours

News

Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn

Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys

News

Novartis raises mid-term sales outlook on pipeline promise

Novartis has raised its guidance for sales growth out to 2029 on the strength of its pipeline and the potential of late-stage R&D assets

News

Novartis gets FDA okay for frontline use of Scemblix in CML

Novartis has picked up a new FDA approval for its chronic myeloid leukaemia therapy Scemblix that it believes is critical to unlocking the drug's blockbuster sales potential.

Novartis bid to block generic Entresto in US suffers setback

Novartis pays $1bn upfront for Huntington's drug from PTC

Kisqali gets early breast cancer approval in Europe

Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn

Novartis raises mid-term sales outlook on pipeline promise

Novartis gets FDA okay for frontline use of Scemblix in CML

Getting predictive technologies to patients, with Concr

Discover a new era of healthcare panel engagement: Grounded ...

Novartis

Editor's Picks